Graeme Smith

Graeme Smith has over 19 years of experience in the pharmaceutical industry. In 2021, they joined Skyhawk Therapeutics as Senior Vice President of Nonclinical Development. Prior to that, they worked at Vertex Pharmaceuticals from 2004 to 2021, in roles such as Vice President, Global Head of Preclinical Safety Assessment & Bioanalysis, Sr. Director, Head of Preclinical Safety Assessment, Sr. Director, Drug Safety Evaluation, Head of Regulatory Toxicology, Director, Toxicology/Drug Safety Evaluation, Associate Director, Toxicology, and Staff Investigator/Sr. Nonclinical Scientist, Toxicology. Before Vertex, Graeme worked at BioReliance from 2002 to 2004 as Laboratory Director.

Graeme Smith obtained a BScH in Life Sciences from Queen's University in 1995 and a Ph.D. in Pharmacology and Toxicology from Queen's University in 2001.